+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07000084

Comparing Gemcitabine Plus BCG Versus BCG Alone for Recurrent High-Grade Non-Muscle Invasive Bladder Cancer A Randomized Phase III Trial Evaluating Treatment Effectiveness and Safety

Led by Alliance for Clinical Trials in Oncology · Updated on 2026-10-02

330

Participants Needed

60

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether adding gemcitabine to intravesical Bacillus Calmette Guerin BCG treatment improves outcomes for patients with recurrent non-muscle invasive bladder cancer NMIBC after prior BCG therapy. This phase III trial compares the combination of gemcitabine, a chemotherapy drug that blocks DNA production, with standard BCG treatment alone. The study aims to assess differences in cancer recurrence, progression, and safety between these treatments. Participants are randomly assigned to one of two groups. One group receives BCG alone, administered intravesically once weekly for six weeks, followed by additional weekly doses at months 3, 6, and 12 if there is no disease progression or unacceptable side effects. The other group receives a combination of gemcitabine and BCG given intravesically on a specific schedule over 10 weeks, with maintenance doses of both drugs at months 3, 6, and 12 under similar conditions. Both groups undergo bladder biopsies, cystoscopy, TURBT procedures, CT or MRI scans, and blood and urine sample collection throughout the study. After completing treatment, participants are followed every three months for two years, then every six months for up to five years from randomization. Researchers monitor high-grade recurrence-free survival as the primary outcome, along with secondary measures such as cancer-free status at three months, complete response rates, durability of response, time to any bladder cancer recurrence, progression-free survival, cystectomy-free survival, and safety through adverse event rates. The study also collects tumor tissue and biological samples for future research.

CONDITIONS

Brief Title

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Research Team

A

Aishwarya Vijendran

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here